drug
eculizumab biosimilar
Marketedupdated 3mo agoby $AMGN AMGEN INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Antibody drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 20 investigational indications.
all catalysts(7)
approval · 7
May 28, 2024
approval
$AMGN415.21-0.63%
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Oct 23, 2024
approval
$AMGN415.21-0.63%
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Jan 30, 2025
approval
$AMGN415.21-0.63%
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Apr 18, 2025
approval
$AMGN415.21-0.63%
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Sep 17, 2025
approval
$AMGN415.21-0.63%
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Nov 24, 2025
approval
$AMGN415.21-0.63%
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Mar 26, 2026
approval
$AMGN415.21-0.63%
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Trials studying eculizumab biosimilar
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that